Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 27.02.18 in Vol 4, No 1 (2018): Jan-Mar

This paper is in the following e-collection/theme issue:

Works citing "Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study"

According to Crossref, the following articles are citing this article (DOI 10.2196/publichealth.9282):

(note that this is only a small subset of citations)

  1. Adenuga BA, Kibuule D, Bamitale KDS, Rennie TW. Effective integration of pharmacovigilance systems at public health facilities in resource-limited settings: A qualitative study. Research in Social and Administrative Pharmacy 2020;16(8):1111
  2. Graham M, Lucas CJ, Schneider J, Martin JH, Hall W. Translational hurdles with cannabis medicines. Pharmacoepidemiology and Drug Safety 2020;
  3. Small SS, Hohl CM, Balka E. Organizational implications of implementing a new adverse drug event reporting system for care providers and integrating it with provincial health information systems. Healthcare Management Forum 2019;32(4):208
  4. Abramova N, Hubbard J, Schertz J, Richter E. Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development. Drug Safety 2019;42(3):453
  5. Güner MD, Ekmekci PE. Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. Journal of Drug Assessment 2019;8(1):13
  6. Peddie D, Small SS, Badke K, Bailey C, Balka E, Hohl CM. Adverse Drug Event Reporting From Clinical Care: Mixed-Methods Analysis for a Minimum Required Dataset. JMIR Medical Informatics 2018;6(2):e10248